Actively Recruiting
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Led by Robert Flavell, MD, PhD · Updated on 2025-11-12
20
Participants Needed
1
Research Sites
167 weeks
Total Duration
On this page
Sponsors
R
Robert Flavell, MD, PhD
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
CONDITIONS
Official Title
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have confirmed multiple myeloma by tissue or cell testing according to IMWG criteria
- At least one myeloma lesion positive on 18F-FDG PET/CT or PET/MRI, defined by uptake greater than liver
- Age 18 years or older
- Total bilirubin less than or equal to 1.5 times the institutional upper limit of normal
- Aspartate aminotransferase (AST) less than or equal to 3 times the institutional upper limit of normal
- Alanine aminotransferase (ALT) less than or equal to 3 times the institutional upper limit of normal
- Creatinine clearance of 60 mL/min or higher or serum creatinine less than or equal to 1.5 times the institutional upper limit of normal
- Ability to understand and sign informed consent
You will not qualify if you...
- Any condition that may prevent compliance with study procedures or affect safety, as judged by the principal investigator
- Pregnant or breastfeeding individuals
- Breastfeeding must be stopped before receiving [89Zr]DFO-YS5
- Females of childbearing potential must have a negative pregnancy test within 72 hours before receiving [89Zr]DFO-YS5
- Females are considered of childbearing potential unless postmenopausal for 12 months or surgically sterilized
- Positive or equivocal pregnancy tests exclude participation
- Unknown or potential risks to unborn or nursing child from [89Zr]DFO-YS5 treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
M
Maya Aslam
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here